VREX vs PHG vs NEOG Stock Comparison

Varex Imaging, Koninklijke Philips and Neogen Prices as of Oct 27, 2026 Peers: Industry group
VREX Varex Imaging Corp
$18.46 +0.1% 1M +54.9% 1Y
Market cap
$776.75M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
PHG Koninklijke Philips Nv
$26.42 +5.8% 1M -8.5% 1Y
Market cap
$25.66B
P/E
13.9x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
9 wins
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.65B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

11 decided of 12

Koninklijke Philips leads on 9 of the 12 questions below (Koninklijke Philips 9, Neogen 1, Varex Imaging 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVREXPHGNEOGLeader
Larger companyMarket capitalisation $776.75M $25.66B $2.65B PHG
Cheaper on earningsLower P/E, profitable companies only 35.1x 13.9x -47.3x PHG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x 13.3x 39.0x PHG
Faster revenue growthRevenue growth, trailing twelve months +5.3% +6.1% -0.3% PHG
More profitableNet margin, trailing twelve months 2.6% 8.9% -6.3% PHG
Better return on capitalReturn on invested capital 6.9% 11.5% -0.2% PHG
Less leveragedLower net debt / EBITDA 2.5x 1.8x 5.4x PHG
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +54.9% -8.5% +100.8% NEOG
Better 5-year returnAnnualised price return, 5 years -7.3%/yr -11.1%/yr -21.4%/yr VREX
Less volatileAnnualised volatility, 1 year 57.5% 28.7% 55.6% PHG
Higher overall scoreMean of the five percentile scores vs peers 51/100 80/100 58/100 PHG

Percentile Scorecard

VREXPHGNEOG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVREXPHGNEOG
Valuation 87 #31 of 227 98 #6 of 227 71 #66 of 227
Growth 23 #168 of 219 95 #11 of 219 50 #110 of 219
Profitability 66 #70 of 206 95 #11 of 206 62 #79 of 206
Financial Health 42 #139 of 238 31 #165 of 238 46 #128 of 238
Shareholder Returns 35 #88 of 134 79 #29 of 134 58 #57 of 134
Overall 51 80 58
  • VREX ranked among 247 companies in Medical Devices and Diagnostics
  • PHG ranked among 247 companies in Medical Devices and Diagnostics
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVREXPHGNEOGSPY
1 month +0.1%+5.8%-9.4% -0.2%
3 months +65.9%+3.4%+35.7% +3.9%
6 months +52.9%-2.6%+33.5% +8.2%
Year to date +58.5%-2.4%+78.4% +12.9%
1 year +54.9%-8.5%+100.8% +12.3%
3 years +6.7%+42.8%-18.6% +87.4%
3 years, per year +2.2%+12.6%-6.6% +23.3%
5 years -31.4%-44.3%-69.9% +67.9%
5 years, per year -7.3%-11.1%-21.4% +10.9%
10 years —-11.3%-35.8% +261.1%
10 years, per year —-1.2%-4.3% +13.7%

Risk

MeasureVREXPHGNEOGSPY
Volatility, 1Y 57.5%28.7%55.6% 12.7%
Downside volatility, 1Y 50.0%28.7%46.5% 12.7%
Beta vs S&P 500, 1Y 1.110.811.45 1.00
Return / volatility, 1Y 0.95-0.301.81 0.97
Max drawdown, 5Y -78.8%-75.6%-90.6% -25.4%
From 52-week high -0.6%-19.7%-10.8% -1.2%
52-week high $18.58$32.91$13.98 $779.14
52-week low $9.32$23.81$5.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVREXPHGNEOG
P/E now vs peer median 35.2xmedian 29.6x 13.6xmedian 29.6x -48.5xmedian 29.6x
P/S now vs peer median 0.9xmedian 2.9x 1.2xmedian 2.9x 3.1xmedian 2.9x
EV/EBITDA now vs peer median 10.2xmedian 17.4x 8.1xmedian 17.4x 30.0xmedian 17.4x
P/FCF now vs peer median -38.5xmedian 22.3x 5.9xmedian 22.3x 54.7xmedian 22.3x
P/B now vs peer median 1.5xmedian 2.3x 1.9xmedian 2.3x 1.3xmedian 2.3x
PEG now vs peer median -9.17median 1.04 0.32median 1.04 1.73median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVREXPHGNEOG
Revenue $865.00M $20.60B $883.99M
Gross profit $296.90M $16.03B $418.98M
Operating income $72.20M $2.65B -$7.38M
Net income $22.40M $1.39B -$56.10M
Free cash flow -$20.20M $4.34B $49.80M
R&D $91.40M $2.00B $19.76M
EPS (diluted) $0.52 $1.91 $-0.26
Cash & equivalents $99.20M $2.04B $172.00M
Total debt $347.10M $9.51B $774.20M
Shares (diluted) 42.60M 962.50M 218.10M
Enterprise value $308.55M $14.77B $1.99B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVREXPHGNEOG
P/E 35.2x 13.6x -48.5x
P/FCF -38.5x 5.9x 54.7x
P/Operating cash flow 68.9x 9.6x 31.9x
P/S 0.9x 1.2x 3.1x
P/B 1.5x 1.9x 1.3x
P/Tangible book 1.6x 2.5x 3.4x
EV/EBITDA 10.2x 8.1x 30.0x
EV/EBIT 14.2x 12.4x -450.7x
EV/Revenue 1.2x 1.6x 3.8x
EV/FCF -50.8x 7.6x 66.8x
EV/Operating cash flow 90.8x 12.4x 39.0x
PEG (3Y EPS CAGR) -9.17 0.32 1.73

Growth

14 metrics
MetricVREXPHGNEOG
Revenue growth (1Y) 5.3% 6.1% -0.3%
Revenue CAGR (3Y) -1.2% 2.3% -1.3%
Gross profit growth (1Y) 6.1% 82.4% 1.8%
Gross profit CAGR (3Y) 1.2% 6.7% -3.1%
Operating income growth (1Y) 297.8% 121.3% 99.3%
Operating income CAGR (3Y) -2.3% 52.0% -29.0%
Net income growth (1Y) 116.7% 293.5% 94.6%
Net income CAGR (3Y) -9.2% 35.6% -28.3%
EPS growth (1Y) 116.1% 539.4% 94.6%
EPS CAGR (3Y) -3.8% 42.2% -28.0%
Operating cash flow growth (1Y) -81.1% 116.7% -1.9%
Operating cash flow CAGR (3Y) -47.6% 53.6% 2.9%
Free cash flow growth (1Y) -155.5% 54.2% 1,631%
Free cash flow CAGR (3Y) -33.5% 45.6% 126.1%

Profitability

14 metrics
MetricVREXPHGNEOG
Gross margin 34.3% 77.8% 47.4%
EBITDA margin 11.7% 19.8% 12.5%
Operating margin 8.3% 12.9% -0.8%
Pretax margin 3.2% 11.9% -7.7%
Net margin 2.6% 8.9% -6.3%
FCF margin -2.3% 21.1% 5.6%
Operating cash flow margin 1.3% 12.9% 9.6%
Return on equity 4.5% 12.7% -2.7%
Return on assets 2.1% 5.4% -1.7%
Return on invested capital 6.9% 11.5% -0.2%
Return on capital employed 8.0% 11.8% -0.2%
Asset turnover 0.8x 0.7x 0.3x
Cash conversion (OCF / net income) 0.5x 1.9x -1.5x
Stock comp / revenue 1.7% 0.7% 1.3%

Financial Health

11 metrics
MetricVREXPHGNEOG
Debt / assets 31.6% 31.2% 23.4%
Debt / equity 0.7x 0.7x 0.4x
Net debt / EBITDA 2.5x 1.8x 5.4x
Debt / FCF -17.2x 2.2x 15.5x
Liabilities / assets 53.6% 57.1% 36.8%
Equity / assets 46.4% 42.9% 63.2%
Interest coverage 1.9x 6.2x –
Current ratio 3.4x 1.3x 3.9x
Quick ratio 1.3x 0.7x 2.1x
Cash ratio 0.5x 0.2x 1.2x
Altman Z-score 2.29 – 1.52

Shareholder Returns

7 metrics
MetricVREXPHGNEOG
Dividend yield – 3.7% –
Net buyback yield -0.4% -0.5% -0.1%
Shareholder yield -0.4% 3.3% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVREXPHGNEOG
Forward P/E 21.2xFY2026 13.3xFY2026 39.0xFY2026
EPS, next fiscal year $0.87FY2026 $1.98FY2026 $0.32FY2026
EPS growth, next FY -3.3%FY2026 +6.5%FY2026 0.0%FY2026
EPS growth, the year after +14.9% -10.1% +31.3%
Revenue, next fiscal year $829.68MFY2026 $21.63BFY2026 $847.28MFY2026
Revenue growth, next FY -1.8%FY2026 +1.8%FY2026 -2.7%FY2026
Revenue growth, the year after +2.3% -8.2% -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVREXPHGNEOG
Held by institutions 95.2% 5.4% 100.0%
Institutions holding 186 363 315
Change in shares held, QoQ -2.7% +0.8% +1.6%
Institutions buying 98 266 151
Institutions selling 58 76 106
Buyers to sellers 1.69 3.50 1.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VREXPHGNEOG
VREX 1.00 0.29 0.25
PHG 0.29 1.00 0.31
NEOG 0.25 0.31 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VREX, PHG and NEOG?

Koninklijke Philips (PHG) is the largest by market capitalisation: Varex Imaging (VREX) $776.75M, Koninklijke Philips (PHG) $25.66B, Neogen (NEOG) $2.65B.

Which stock is cheaper, VREX, PHG and NEOG?

Koninklijke Philips (PHG) trades on the lowest price-to-earnings ratio (Varex Imaging (VREX) 35.1x, Koninklijke Philips (PHG) 13.9x, Neogen (NEOG) -47.3x). On next year's consensus earnings, Koninklijke Philips (PHG) is cheapest (Varex Imaging (VREX) 21.2x, Koninklijke Philips (PHG) 13.3x, Neogen (NEOG) 39.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Koninklijke Philips (PHG) grew revenue fastest over the trailing twelve months: Varex Imaging (VREX) +5.3%, Koninklijke Philips (PHG) +6.1%, Neogen (NEOG) -0.3%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Varex Imaging (VREX) 2.6%, Koninklijke Philips (PHG) 8.9%, Neogen (NEOG) -6.3%). On return on invested capital, Koninklijke Philips (PHG) leads (Varex Imaging (VREX) 6.9%, Koninklijke Philips (PHG) 11.5%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Varex Imaging (VREX) +54.9%, Koninklijke Philips (PHG) -8.5%, Neogen (NEOG) +100.8%. Over five years, Varex Imaging (VREX) compounded fastest (Varex Imaging (VREX) -7.3%/yr, Koninklijke Philips (PHG) -11.1%/yr, Neogen (NEOG) -21.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Varex Imaging (VREX) 57.5%, Koninklijke Philips (PHG) 28.7%, Neogen (NEOG) 55.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, VREX, PHG and NEOG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.